5HT3-receptor antagonists as antiemetics in cancer

Drug and Therapeutics Bulletin

Volumn 43, Issue 8, 2005, Pages 57-62

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOMPERIDONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANISETRON; IFOSFAMIDE; IRINOTECAN; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; PLACEBO; PROCHLORPERAZINE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SUBSTANCE P; TAXANE DERIVATIVE; TROPISETRON; UNINDEXED DRUG; VINCA ALKALOID; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; QUINOLIZINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ABDOMINAL DISCOMFORT; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; FATIGUE; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; META ANALYSIS; NAUSEA AND VOMITING; PRESCRIPTION; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; TREATMENT WITHDRAWAL; UNITED KINGDOM; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; DRUG ANTAGONISM; NAUSEA; NEOPLASM; PRACTICE GUIDELINE; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; GRANISETRON; HUMANS; INDOLES; ISOQUINOLINES; NAUSEA; NEOPLASMS; ONDANSETRON; PRACTICE GUIDELINES; QUINOLIZINES; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 23344433802     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2005.43857     Document Type: Review

References (42)

1. Fallowfield LJ. Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer 1992; 28A (suppl 1): S39-41.
2. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003; 8: 187-98.
3. Ondansetron to prevent chemotherapy-induced vomiting. DTB 1992; 30: 21-3.
4. Gralla RJ et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
5. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 1998; 9: 811-9.
6. Cubeddu LX et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810-6.
7. Wilder-Smith OH et al. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993; 72: 2239-41.
8. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15: 124-30.
9. 1 antagonists; a new class of antiemetics. Br J Cancer 2003; 88: 1823-7.
10. Feyer PC et al. Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 1998; 6: 253-60.
11. Scarantino CW et al. On the mechanism of radiation-induced emesis: the role of serotonin. Int J Radiat Oncol Biol Phys 1994; 30: 825-30.
12. Asif M et al. Palonosetron. Drugs 2004; 64: 1125-32.
13. Kris MG et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 1987; 60: 2816-22.
14. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997; 33: 66-74.
15. 3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Practice Guideline Report #12-3 [online]. Available: http://www.cancercare.on.ca/pdf/full12_3.pdf [Accessed 19 July 2005].
16. Simpson K et al. Tropisetron. An update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000; 59: 1297-315.
17. del Giglio A et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Results of a meta-analysis of randomized controlled trials. Cancer 2000; 89: 2301-8.
18. Mantovani G et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996; 77: 941-8.
19. de Wit R et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001; 85: 1099-101.
20. Cunningham D et al. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996; 7: 277-82.
21. 3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14: 644-51.
22. Ioannidis JP et al. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-22.
23. Seynaeve C et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992; 66: 192-7.
24. Ettinger DS et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996; 78: 144-51.
25. Gralla RJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 1568-73.
26. Perez EA et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998; 16: 754-60.
27. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
28. De Mulder PH et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990; 113: 834-40.
29. Esseboom EU et al. Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. Neth J Med 1995; 47: 12-7.
30. Kris MG et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-14.
31. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-9.
32. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307: 1476-80.
33. 3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Eur J Cancer 1998; 34: 1836-44.
34. Franzén L et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996; 7: 587-92.
35. Priestman TJ et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 1990; 2: 71-5.
36. Priestman TJ et al. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol 1993; 5: 358-63.
37. Spitzer TR et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12: 2432-8.
38. Prentice HG et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15: 445-8.
39. Hewitt M et al. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. Clin Oncol 1993; 5: 11-4.
40. Dick GS et al. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995; 73: 243-5.
41. Hählen K et al. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995; 126: 309-13.
42. Alvarez O et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995; 17: 145-50.